|
|
| | RIPK1-IN-19 Basic information |
| Product Name: | RIPK1-IN-19 | | Synonyms: | RIPK1-IN-19;1H-Indole-3-carboxamide, 5-[2-[(cyclopropylcarbonyl)amino][1,2,4]triazolo[1,5-a]pyridin-7-yl]-N-[(1S)-1-(3-fluorophenyl)ethyl]-1-methyl-;(S)-5-(2-(Cyclopropanecarboxamido)-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(1-(3-fluorophenyl)ethyl)-1-methyl-1H-indole-3-carboxamide | | CAS: | 2763831-43-0 | | MF: | C28H25FN6O2 | | MW: | 496.54 | | EINECS: | | | Product Categories: | | | Mol File: | 2763831-43-0.mol |  |
| | RIPK1-IN-19 Chemical Properties |
| density | 1.428±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 12.237±0.46(predicted) | | form | Solid | | color | Light brown to brown |
| | RIPK1-IN-19 Usage And Synthesis |
| Uses | RIPK1-IN-19 (compound 10b) is a selective RIPK1 inhibitor (IC50=15 nM). RIPK1-IN-19 displays potent protective activity in TNFα-induced systemic inflammatory response syndrome (SIRS) model and Imiquimod (IMQ)-induced psoriasis model. RIPK1-IN-19 can be used in research on inflammation and immune system diseases[1]. | | IC 50 | RIPK1: 15 nM (IC50) | | References | [1] Zhang L, et al. From Hit to Lead: Structure-Based Optimization of Novel Selective Inhibitors of Receptor-Interacting Protein Kinase 1 (RIPK1) for the Treatment of Inflammatory Diseases. J Med Chem. 2024 Jan 11;67(1):754-773. DOI:10.1021/acs.jmedchem.3c02102 |
| | RIPK1-IN-19 Preparation Products And Raw materials |
|